F98 EGFR (ATCC® CRL-2948)

Organism: Rattus norvegicus, rat  /  Tissue: brain  /  Disease: undifferentiated malignant glioma

Permits and Restrictions

View Permits

Organism Rattus norvegicus, rat
Tissue brain
Product Format frozen
Morphology glial
Culture Properties adherent
Biosafety Level 2
Disease undifferentiated malignant glioma
Age fetus, 20 days gestation
Applications

This cell line has been used for in vivo studies of molecular targeting of EGFR in synegeneic Fischer Rats using either the ligand EGF RefBarth RF, et al. Molecular targeting of the epidermal growth factor receptor for neutron capture therapy of gliomas. Cancer Res. 62(11): 3159-3166, 2002. PubMed: 12036929 or monoclonal antibodies directed against it. RefWu G, et al. Molecular targeting and treatment of an epidermal growth factor receptor-positive glioma using boronated cetuximab. Clin. Cancer Res. 13(4): 1260-1268, 2007. PubMed: 17317838


Storage Conditions liquid nitrogen vapor phase
Images
Derivation
The F98EGFR was produced by transfecting parental F98 rat glioma cells (ATCC CRL-2397) with an expression vector containing human, wildtype EGFR cDNA.
Receptor Expression
Epidermal Growth Factor Receptor (EGFR), expressed (verified at ATCC)
Tumorigenic YES
Effects
tumorigenic in syngeneic Fischer rats
Comments

F98EGFR cells express approximately 5 x 105 non-functional EGFR sites per cell compared with an undetectable number of EGFR sites on F98 parental cells.

Complete Growth Medium The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium:
  • 0.2 mg/ml G -418
  • fetal bovine serum to a final concentration of 10%
  • Subculturing
    Volumes used in this protocol are for 75 cm2 flasks; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes.
    1. Remove and discard culture medium.
    2. Briefly rinse the cell layer with Ca++/Mg++ free Dulbecco's phosphate-buffered saline (D-PBS) or 0.05% (w/v) Trypsin - 0.53 mM EDTA solution to remove all traces of serum which contains trypsin inhibitor.
    3. Add 2.0 to 3.0 mL of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
      Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
    4. Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
    5. Add appropriate aliquots of the cell suspension to new culture vessels.


    Note: If cells are cultured continuously, add 0.6 mg/mL G-418 to the complete growth medium for a passage about once a month.

    Subcultivation ratio: A subcultivation ratio of 1:6 to 1:10 is recommended.

    Medium renewal: Every 2 to 3 days.
    Cryopreservation
    Freeze medium: complete growth medium, 95%; DMSO, 5%
    liquid nitrogen vapor phase
    Culture Conditions
    Temperature: 37°C
    Atmosphere: air, 95%; carbon dioxide (CO2), 5%
    Name of Depositor RF Barth
    Year of Origin May 1999
    References

    Yang W, et al. Convection enhanced delivery of boronated epidermal growth factor for molecular targeting of EGFR positive gliomas. Cancer Res. 62: 6552-6558, 2002. PubMed: 12438250

    Barth RF, et al. Molecular targeting of the epidermal growth factor receptor for neutron capture therapy of gliomas. Cancer Res. 62(11): 3159-3166, 2002. PubMed: 12036929

    Wu G, et al. Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates. Mol. Cancer Ther. 5(1): 52-59, 2006. PubMed: 16432162.

    Wu G, et al. Molecular targeting and treatment of an epidermal growth factor receptor-positive glioma using boronated cetuximab. Clin. Cancer Res. 13(4): 1260-1268, 2007. PubMed: 17317838

    Yang W, et al. Molecular targeting and treatment of composite EGFR and EGFRvIII-positive gliomas using boronated monoclonal antibodies. Clin. Cancer Res. 14(3): 883-891, 2008. PubMed: 18245552

    Notice: Necessary PermitsPermits

    These permits may be required for shipping this product:

    • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
    Basic Documentation
    Other Documentation
    References

    Yang W, et al. Convection enhanced delivery of boronated epidermal growth factor for molecular targeting of EGFR positive gliomas. Cancer Res. 62: 6552-6558, 2002. PubMed: 12438250

    Barth RF, et al. Molecular targeting of the epidermal growth factor receptor for neutron capture therapy of gliomas. Cancer Res. 62(11): 3159-3166, 2002. PubMed: 12036929

    Wu G, et al. Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates. Mol. Cancer Ther. 5(1): 52-59, 2006. PubMed: 16432162.

    Wu G, et al. Molecular targeting and treatment of an epidermal growth factor receptor-positive glioma using boronated cetuximab. Clin. Cancer Res. 13(4): 1260-1268, 2007. PubMed: 17317838

    Yang W, et al. Molecular targeting and treatment of composite EGFR and EGFRvIII-positive gliomas using boronated monoclonal antibodies. Clin. Cancer Res. 14(3): 883-891, 2008. PubMed: 18245552